Depression is a highly prevalent and under-treated condition in the U.S., and worldwide. Despite the availability of safe and effective medications, a high proportion of patients do not achieve remission of symptoms even after switching treatments. Adequate measurement of symptom improvement from a patient’s perspective is imperative for the development of novel therapies. The Depression Working Group is developing ed a new PRO measure (i.e., Symptoms of Major Depressive Disorder Scale [SMDDS]) for use as an efficacy endpoint measure in clinical trials for major depressive disorder.
Working Group Sponsors
Eli Lilly and Company
Janssen Pharmaceutical Companies of Johnson & Johnson
Sunovion Pharmaceuticals Inc.